Ignore the GAAP loss — the quarter's result is a structural transformation with one-time charges and a $50M PIPE. The next catalyst is CUE-221 Phase 2 data (end-Q3 2026), which carries binary risk/reward. Monitor for the data readout and any early efficacy signal.
Price Chart
Executive Summary
Cue Biopharma reported Q2 2026 net loss of $153.1M on revenue of $7.9M, well above consensus estimates on both lines, but the headline losses are driven by one-time non-cash and transaction-related charges from the CUE-221 license and $50M PIPE financing. The stock is likely to trade on the CUE-221 Phase 2 data catalyst expected by end-Q3 2026, not the reported accounting quarter.
Key Financial Metrics
Key Facts
- Revenue $7.9M in Q2 2026 vs $3.0M in Q2 2025, driven by a Boehringer Ingelheim collaboration milestone
- Net loss $153.1M in Q2 2026 vs $8.5M in Q2 2025, largely due to $63.1M non-cash loss on warrant issuance from Ascendant license and ~$56M one-time operating expenses
- Cash and cash equivalents $17.4M at June 30, 2026, enhanced by $50M PIPE closed after quarter end
- CUE-221 IND submitted to FDA for food allergy; Phase 2 data in Chronic Spontaneous Urticaria anticipated by end of Q3 2026
- CUE-401 IND and Phase 1 initiation expected by year-end 2026
Financial Impact
Revenue $7.9M beat $3.0M consensus but net loss $153.1M far exceeded consensus $1.69/share loss; impact driven by non-recurring license/warrant charges
Risk Factors
- CUE-221 Phase 2 failure would impair the entire pipeline thesis and likely push stock below cash value
- Runway may be short without further financing beyond the $50M PIPE given ongoing R&D spend (annualized ~$100M operating losses)
- Reliance on single late-stage asset (CUE-221) in a competitive allergy space
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345611 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 11d ago | Insider Cluster | $18.67 $16.71 | ▲ +10.50% | ▲ +9.39% | $18.66 (+0.05%) |
Oct 13, 2026 12d ago | 144 | $18.60 $18.67 | ▲ +0.38% | ▲ +0.09% | $18.66 (+0.32%) |
Oct 8, 2026 18d ago | SC 13G/A | $22.33 $27.66 | ▲ +23.87% | ▲ +23.27% | $18.66 (−16.44%) |
Sep 21, 2026 5w ago | 8-K | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.66 (−33.99%) |
Sep 20, 2026 5w ago | Press Release | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.66 (−33.99%) |
Aug 21, 2026 9w ago | EFFECT | $23.98 $23.18 | ▲ +3.34% | ▲ +3.04% | $18.66 (+22.19%) |
Aug 17, 2026 10w ago | Insider Cluster | $25.70 $26.28 | ▼ −2.26% | ▼ −2.05% | $18.66 (+27.39%) |
Aug 14, 2026 10w ago | Press Release | $27.64 $25.70 | ▼ −7.02% | ▼ −6.34% | $18.66 (−32.49%) |
Aug 13, 2026 10w ago | 144 | $34.20 $27.64 | ▼ −19.18% | ▼ −18.71% | $18.66 (−45.44%) |
Jul 9, 2026 15w ago | Press Release | $36.78 $30.92 | ▼ −15.93% | ▼ −15.17% | $18.66 (−49.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers